Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. US Stem Cell's annualizedGross Profit for the quarter that ended in Dec. 2022 was $0.06 Mil.
US Stem Cell's average Total Assets over the quarter that ended in Dec. 2022 was $0.12 Mil. Therefore, US Stem Cell's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2022 was 50.00%.
US Stem Cell Gross-Profit-to-Asset % Historical Data
The historical data trend for US Stem Cell's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of US Stem Cell's Gross-Profit-to-Asset %
For the Biotechnology subindustry, US Stem Cell's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
US Stem Cell's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, US Stem Cell's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where US Stem Cell's Gross-Profit-to-Asset % falls into.
US Stem Cell Gross-Profit-to-Asset % Calculation
US Stem Cell's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Dec. 2022) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
US Stem Cell Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of US Stem Cell's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
USRM has been successfully added to your 